Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin and Pucotenlimab as Neoadjuvant Therapy in Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
NCT07665190Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Jul 2026; status: recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT07665190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07665190.